HIV drug may also treat AMD

Article

A recent study published in Science found that drugs that have been used to treat HIV/AIDS for 30 years can also be used to treat age-related macular degeneration (AMD), as well as other inflammatory disorders, due to previously undiscovered intrinsic and inflammatory activity those drugs possess.

Lexington, KY-A recent study published in Science found that drugs that have been used to treat HIV/AIDS for 30 years can also be used to treat age-related macular degeneration (AMD), as well as other inflammatory disorders, due to previously undiscovered intrinsic and inflammatory activity those drugs possess.

Nucleoside reverse transcriptase inhibitors (NRTIs) are the most widely used class of anti-HIV drugs and are thought to be therapeutic in HIV/AIDS patients because they target the enzyme reverse transcriptase, which is critical for replication of HIV.

Determining the value in genetic testing for AMD

Researchers report that multiple FDA-approved NRTIs prevented retinal degeneration in a mouse model of dry AMD. Surprisingly, this effect of NRTIs in the eye was not due to the well-known function of these drugs to inhibit reverse transcriptase. Instead, NRTIs blocked an innate immune pathway called the inflammasome, even in experimental systems in which the NRTIs were not capable of blocking reverse transcriptase. 

The study also showed that NRTIs were effective in other disease models that share common signaling pathways with the dry AMD model, including wet AMD and graft-versus-host disease, which is the major obstacle preventing successful allogeneic hematopoietic stem cell transplantation. 

"Repurposing of NRTIs could be advantageous, for one, because they are very inexpensive," says Benjamin Fowler, PhD, the study’s lead author. “Moreover, through decades of clinical experience, we know that some of the drugs we tested are incredibly safe. Since these NRTIs are already FDA approved, they could be rapidly and inexpensively translated into therapies for a variety of untreatable or poorly treatable conditions." 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Carolyn Majcher, OD, FAAO, detailed a talk she gave alongside Mary Beth Yackey, OD, at Optometry's Meeting 2025.
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD, and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.
© 2025 MJH Life Sciences

All rights reserved.